2023 World Conference on Lung Cancer (Posters)-EP13.01. Patient-Specific Factors as Prognostic Biomarkers in Extensive Disease SCLC

EP13.01. Patient-Specific Factors as Prognostic Biomarkers in Extensive Disease SCLC - PDF(Abstract)

Pdf Summary

This study examined the prognostic significance of patient-specific factors in patients with extensive disease small cell lung cancer (SCLC) treated with chemo-immunotherapy. The researchers conducted a retrospective cohort study including patients with advanced SCLC who received first-line combination chemo-immunotherapy. They measured patient-specific factors such as sex and Eastern Cooperative Oncology Group Performance Status (ECOG-PS), as well as hematological parameters including neutrophil-lymphocyte ratio (NLR) and lactate dehydrogenase (LDH) at the start of treatment. They also measured serum tumor markers (STM) at baseline and restaging evaluations.<br /><br />The study included 70 patients, with 49% women and a mean age of 63 years. They found a significant difference in median overall survival (OS) between men and women, with women having a longer OS. Women also had a significantly longer progression-free survival (PFS) compared to men. ECOG PS was also associated with a significant difference in OS, with better outcomes for patients with lower ECOG PS scores. However, ECOG PS was not associated with significant differences in PFS. Higher baseline LDH values were found to be associated with worse OS outcomes. Initial NLR did not show any significant associations with OS or PFS.<br /><br />These findings suggest that patient-specific biomarkers, such as sex, ECOG-PS, and initial LDH values, can have prognostic significance for advanced SCLC patients treated with chemo-immunotherapy. Understanding these factors can help in predicting outcomes and potentially guide treatment decisions for patients with extensive disease SCLC.

Asset Subtitle

Romana Wass

Meta Tag

Speaker Romana Wass

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

prognostic significance

patient-specific factors

SCLC

chemo-immunotherapy

ECOG-PS

LDH

serum tumor markers

overall survival

progression-free survival

biomarkers